An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The objective of this clinical trial is to investigate the efficacy and safety of Enlonstobart combined with concurrent chemoradiotherapy following induction chemotherapy for locally advanced cervical cancer. The primary questions it aims to address are: Can the Enlonstobart combination regimen improve the objective response rate and disease control rate in patients with locally advanced cervical cancer? What is the safety and tolerability profile of this combination regimen, and will any unexpected serious adverse events occur? Participants will: Receive induction therapy with Enlonstobart in combination with chemotherapy agents (e.g., paclitaxel plus platinum); Receive Enlonstobart in combination with concurrent chemoradiotherapy (external beam radiation therapy plus brachytherapy, with concurrent chemotherapy); Undergo regular tumor imaging evaluations (CT/MRI) and hematological safety assessments; Cooperate in completing efficacy assessments, adverse event documentation, and long-term follow-up.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Potwierdzony rak szyjki macicy (raki płaskonabłonkowe, gruczolakowate lub mieszane)
- •Zaawansowany rak szyjki macicy (stadium FIGO III-IVA) bez wcześniejszego leczenia
- •Dobry stan ogólny (wynik ECOG 0-1)
- •Prawidłowa funkcja serca, wątroby, nerek i krwi
- •Co najmniej jeden guz mierzalny do oceny
- •Dla kobiet w wieku rozrodczym: ujemny test ciążowy i stosowanie antykoncepcji
- •Dobrowolnie podpisana zgoda na udział w badaniu
✗ Disqualifies
- •Historia innego nowotworu złośliwego w ciągu ostatnich 3 lat (z pewnymi wyjątkami)
- •Aktywne gruźlica lub historia gruźlicy
- •Historia chorób płuc ze stanów zapalnych (zapalenie tkanki płucnej)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 20, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (2)
Tianjin Cancer Hospital Airport Branch
Tianjin, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Trial contact
Liming Xu Liming Xu
Yaomei Ma
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.